{"id":"prednisone-cytarabine-vincristine","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Immunosuppression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prednisone is a corticosteroid that reduces inflammation and suppresses immune function. Cytarabine is a cytidine analog that inhibits DNA synthesis and is incorporated into DNA, causing cell death in rapidly dividing cells. Vincristine is a vinca alkaloid that binds to tubulin and disrupts microtubule formation, arresting cells in metaphase. Together, this regimen targets leukemic blasts through multiple mechanisms.","oneSentence":"This combination uses a corticosteroid to suppress immune responses and two chemotherapy agents to kill rapidly dividing cancer cells through different mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:30:03.370Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL) in pediatric patients"},{"name":"Acute myeloid leukemia (AML) in pediatric patients"}]},"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT02405676","phase":"PHASE2, PHASE3","title":"BNHL-2015 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2015-01-01","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":200},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT02723994","phase":"PHASE2","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-30","conditions":"Leukemia","enrollment":171},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT05157971","phase":"PHASE1","title":"Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-03-17","conditions":"B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia","enrollment":24},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":40},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT02523976","phase":"PHASE2","title":"Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2015-08-01","conditions":"Acute,Leukemia, Lymphoid","enrollment":30},{"nctId":"NCT02858804","phase":"PHASE4","title":"EDOCH Alternating With DHAP for New Diagnosed Younger MCL","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-01","conditions":"Mantle Cell Lymphoma","enrollment":55},{"nctId":"NCT03808610","phase":"PHASE1, PHASE2","title":"Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-03","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":"Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":24},{"nctId":"NCT00501826","phase":"PHASE2","title":"Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07-11","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":160},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT07297173","phase":"PHASE1","title":"Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-12-01","conditions":"Relapsed Leukemia, Refractory Leukemia","enrollment":5},{"nctId":"NCT05761171","phase":"PHASE2","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-01-08","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","enrollment":78},{"nctId":"NCT01371630","phase":"PHASE1, PHASE2","title":"Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-08-26","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Burkitt-Like Lymphoma With 11q Aberration","enrollment":276},{"nctId":"NCT06387121","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-02","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":53},{"nctId":"NCT01046825","phase":"PHASE2, PHASE3","title":"Mature B-Cell Lymphoma And Leukemia Study III","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-09-09","conditions":"Mature B-Cell Lymphoma","enrollment":128},{"nctId":"NCT01424982","phase":"PHASE2","title":"Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-10-05","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission","enrollment":88},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT02003222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-19","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":488},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia","enrollment":5949},{"nctId":"NCT03589326","phase":"PHASE3","title":"A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2018-10-04","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)","enrollment":245},{"nctId":"NCT02877303","phase":"PHASE2","title":"Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-01","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT00136435","phase":"PHASE2","title":"A Study in Adults With Untreated Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2002-06","conditions":"Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT05645718","phase":"PHASE2","title":"Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-07-14","conditions":"Leukemia","enrollment":27},{"nctId":"NCT02356159","phase":"PHASE1, PHASE2","title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-24","conditions":"Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT01920737","phase":"PHASE2","title":"A Novel \"Pediatric-Inspired\" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-08-07","conditions":"Leukemia","enrollment":39},{"nctId":"NCT07168980","phase":"PHASE2, PHASE3","title":"Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2025-07-01","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":87},{"nctId":"NCT07152041","phase":"PHASE3","title":"Newly-diagnosed Pediatric Ph-positive B-ALL Protocol","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-28","conditions":"Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic","enrollment":150},{"nctId":"NCT06882057","phase":"PHASE2, PHASE3","title":"Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-03","conditions":"Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)","enrollment":3000},{"nctId":"NCT05032183","phase":"PHASE1, PHASE2","title":"Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-17","conditions":"Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT05660473","phase":"PHASE2","title":"Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-08-01","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":100},{"nctId":"NCT02420717","phase":"PHASE2","title":"Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-07-15","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":11},{"nctId":"NCT03384654","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-14","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":47},{"nctId":"NCT02205762","phase":"PHASE2, PHASE3","title":"LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis","status":"RECRUITING","sponsor":"North American Consortium for Histiocytosis","startDate":"2016-11-02","conditions":"Langerhans Cell Histiocytosis","enrollment":1400},{"nctId":"NCT04752163","phase":"PHASE1, PHASE2","title":"DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-03-25","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":17},{"nctId":"NCT05959720","phase":"","title":"Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil","status":"RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2023-09-05","conditions":"Acute Lymphoid Leukemia, Minimal Residual Disease, Gene Abnormality","enrollment":180},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT00408005","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01-30","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":1895},{"nctId":"NCT03643276","phase":"PHASE3","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","status":"RECRUITING","sponsor":"Martin Schrappe","startDate":"2018-07-15","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":5000},{"nctId":"NCT05303792","phase":"PHASE2","title":"Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-06-09","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma","enrollment":68},{"nctId":"NCT03792256","phase":"PHASE1","title":"Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2019-04-11","conditions":"Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma","enrollment":12},{"nctId":"NCT04043494","phase":"PHASE3","title":"International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"University Hospital Muenster","startDate":"2019-08-23","conditions":"Lymphoblastic Lymphoma, Childhood","enrollment":683},{"nctId":"NCT01865110","phase":"PHASE3","title":"R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2013-11","conditions":"Mantle Cell Lymphoma","enrollment":623},{"nctId":"NCT02828358","phase":"PHASE2","title":"Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-01","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":78},{"nctId":"NCT00390793","phase":"PHASE2","title":"Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-09-28","conditions":"Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":107},{"nctId":"NCT04475731","phase":"PHASE2","title":"Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2021-05-04","conditions":"Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse","enrollment":67},{"nctId":"NCT02633137","phase":"PHASE2","title":"Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-12-14","conditions":"Mantle Cell Lymphoma, Untreated","enrollment":49},{"nctId":"NCT05326516","phase":"PHASE1","title":"A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia","status":"COMPLETED","sponsor":"Syndax Pharmaceuticals","startDate":"2022-03-09","conditions":"Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia","enrollment":30},{"nctId":"NCT03488225","phase":"PHASE2","title":"Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-03-28","conditions":"Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":4},{"nctId":"NCT00557193","phase":"PHASE3","title":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-01-15","conditions":"Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia","enrollment":218},{"nctId":"NCT00381680","phase":"PHASE3","title":"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-03","conditions":"B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia","enrollment":275},{"nctId":"NCT04845035","phase":"PHASE2","title":"Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"WITHDRAWN","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2024-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT06263530","phase":"","title":"Prognostic Significance of ctDNA in HL","status":"RECRUITING","sponsor":"Interni hematologicka klinika FNKV","startDate":"2022-01-02","conditions":"Prognostic Cancer Model","enrollment":500},{"nctId":"NCT06255704","phase":"PHASE2","title":"A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Province Cancer Hospital","startDate":"2024-03-15","conditions":"Mantle Cell Lymphoma","enrollment":23},{"nctId":"NCT01186328","phase":"PHASE1","title":"EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08-24","conditions":"Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell","enrollment":6},{"nctId":"NCT06211452","phase":"PHASE3","title":"Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Grupo Argentino de Tratamiento de la Leucemia Aguda","startDate":"2007-08-01","conditions":"AML, Pediatric AML","enrollment":258},{"nctId":"NCT01858922","phase":"PHASE2","title":"Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2012-12-19","conditions":"Hodgkin Disease","enrollment":40},{"nctId":"NCT05444712","phase":"NA","title":"Transplantation After Complete Response In Patients With T-cell Lymphoma","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2022-08-01","conditions":"Peripheral T Cell Lymphoma","enrollment":204},{"nctId":"NCT00101101","phase":"PHASE2","title":"Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2004-07","conditions":"Lymphoma","enrollment":43},{"nctId":"NCT03962465","phase":"PHASE1","title":"Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","startDate":"2022-07-22","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":36},{"nctId":"NCT00039130","phase":"PHASE2","title":"Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2002-05","conditions":"Leukemia, Lymphoma","enrollment":105},{"nctId":"NCT01484093","phase":"PHASE1, PHASE2","title":"Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-11-29","conditions":"Mantle Cell Lymphoma","enrollment":96},{"nctId":"NCT00003388","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-07-26","conditions":"Lymphoma","enrollment":38},{"nctId":"NCT02396043","phase":"PHASE2","title":"Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-03","conditions":"Lymphoma, Lymphoblastic","enrollment":50},{"nctId":"NCT00002514","phase":"PHASE3","title":"Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1993-05-07","conditions":"Leukemia","enrollment":1929},{"nctId":"NCT01859819","phase":"PHASE2","title":"Treatment for Advanced B-Cell Lymphoma","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2013-01","conditions":"Diffuse Large Cell Lymphoma, Burkitt's Lymphoma, High Grade B-cell Lymphoma","enrollment":45},{"nctId":"NCT02042391","phase":"PHASE2","title":"Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy","status":"COMPLETED","sponsor":"Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH","startDate":"2015-02-03","conditions":"Posttransplant Lymphoproliferative Disorder","enrollment":60},{"nctId":"NCT00549848","phase":"PHASE3","title":"Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-10-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":600},{"nctId":"NCT04773366","phase":"PHASE3","title":"A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol","status":"RECRUITING","sponsor":"Shanghai Children's Medical Center","startDate":"2018-07-01","conditions":"Langerhans Cell Histiocytosis","enrollment":200},{"nctId":"NCT03564470","phase":"PHASE2, PHASE3","title":"Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-02-14","conditions":"Leukemia, Leukemia, Acute, Leukemia, Lymphoblastic","enrollment":120},{"nctId":"NCT01451515","phase":"PHASE2","title":"NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-05-25","conditions":"Lymphoblastic Lymphoma","enrollment":23},{"nctId":"NCT01117441","phase":"PHASE3","title":"International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2010-06","conditions":"Leukemia","enrollment":6136},{"nctId":"NCT02043587","phase":"PHASE2","title":"Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2014-01","conditions":"Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma","enrollment":31},{"nctId":"NCT05326984","phase":"NA","title":"Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Hospital General de Mexico","startDate":"2021-02-09","conditions":"Acute Lymphoblastic Leukemia","enrollment":20},{"nctId":"NCT02481310","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Northwestern University","startDate":"2015-10-28","conditions":"Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":38},{"nctId":"NCT02776605","phase":"PHASE2","title":"Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2016-06","conditions":"ALL","enrollment":30},{"nctId":"NCT05026229","phase":"NA","title":"A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-09-06","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia, ALL, Adult","enrollment":60},{"nctId":"NCT05049473","phase":"PHASE2","title":"Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2014-01","conditions":"Mature B-Cell Leukemia Burkitt Type, Burkitt Lymphoma (BL), Unclassifiable Lymphoma Between DCBL and BL","enrollment":100},{"nctId":"NCT01156883","phase":"NA","title":"Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2010-04","conditions":"Leukemia","enrollment":76},{"nctId":"NCT04736914","phase":"PHASE2","title":"Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-01-31","conditions":"Mantle Cell Lymphoma","enrollment":47},{"nctId":"NCT01941680","phase":"","title":"High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant","status":"COMPLETED","sponsor":"University Hospital Center of Martinique","startDate":"2013-10-31","conditions":"T-cell Lymphoma, Leukaemia","enrollment":20},{"nctId":"NCT00075725","phase":"PHASE3","title":"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2003-12-29","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia","enrollment":3154},{"nctId":"NCT00671034","phase":"PHASE3","title":"Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-07-21","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia","enrollment":166},{"nctId":"NCT00866307","phase":"PHASE1","title":"Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-02-23","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia","enrollment":104},{"nctId":"NCT00302003","phase":"PHASE3","title":"Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2006-02","conditions":"Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma","enrollment":287},{"nctId":"NCT00003650","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"UNICANCER","startDate":"1997-02","conditions":"Lymphoma","enrollment":179}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Prednisone+Cytarabine+vincristine","genericName":"Prednisone+Cytarabine+vincristine","companyName":"Shanghai Children's Medical Center","companyId":"shanghai-children-s-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses a corticosteroid to suppress immune responses and two chemotherapy agents to kill rapidly dividing cancer cells through different mechanisms. Used for Acute lymphoblastic leukemia (ALL) in pediatric patients, Acute myeloid leukemia (AML) in pediatric patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}